前列腺癌患者血清miR-152、miR-32表达及其意义

doi:10.3969/j.issn.1671-7171.2020.06.012

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the changes of serum miR-152 and mir-32 levels in patients with prostate cancer and their relationship with pathological stage and Gleason score. 【Methods】From January 2016 to may 2018, patients with prostate cancer (observation group,n=80) and patients with prostate hyperplasia (control group,n=80) were selected. The serum levels of miR-152 and miR-32 were detected and compared between the two groups, and stratified analysis was performed according to the pathological stage, PSA and Gleason score. Hierarchical analysis was performed according to pathological staging, PSA and Gleason scores. 【Results】 The level of serum miR-32 in the observation group was significantly higher than that in the control group (P<0.05); the level of serum miR-152 in the observation group was significantly lower than that in the control group (P<0.05). There was significant difference in serum miR-152 level between patients with prostate cancer of different pathological stages and lymph node metastasis (P<0.05); there was no significant difference in serum miR-152 level of prostate cancer patients with different Gleason scores (P>0.05). There were statistically significant differences in serum mir-32 levels among prostate cancer patients with different pathological stages, lymph node metastasis and Gleason score (P<0.05).【Conclusion】 The serum miR-152 level of prostate cancer patients decreased significantly, the miR-32 level increased significantly, and both are closely related to the clinicopathological characteristics of the patients.

Key words： Prostatic Neoplasms/PA MicroRNAs

Received: 29 November 2018

PACS:

R737.25

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2020.06.012 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2020/V37/I6/840

[1] 史涛,杭震宇,沈露明.LIMK1和Cofilin 蛋白在前列腺癌组织中的表达及其临床意义[J].医学临床研究,2020,37(4):525-526.
[2] 杨明,彭煜,朱文静. miRNAs表达在前列腺癌中的研究进展[J].大连医科大学学报,2016,38(03):302-306.
[3] 杨柳,许有涛,邱满堂,等. 长链非编码RNA前列腺癌非编码核糖核酸1在结直肠癌组织中的上调对增殖及细胞周期的影响[J].中华实验外科杂志,2015,32(9):2172-2174.
[4] 许文婷,贾英杰,李小江,等. miRNA在前列腺癌中的研究进展[J].中华男科学杂志,2015,21(05):458-462.
[5] Chao M, Lim Joon D, Khoo V, et al. The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial[J].World J Urol,2018,28(6):45-47.
[6] Nettey OS, Walker AJ, Keeter MK, et al. Self-reported Black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors[J].Urol Oncol,2018,36(11):501.
[7] 王亚民,宋乐彬,张嘉宜,等. 异常表达的长链非编码RNA与前列腺癌关系的研究进展[J].中华男科学杂志,2015,21(10):945-948.
[8] 戴金华,竺展坤,廖于峰,等. 循环miR-152与miR-221在前列腺癌患者血清中的表达水平及临床意义[J].中国卫生检验杂志,2015,25(5):673-675.
[9] 陈军锋,廖于峰,马建波,等. 循环miR-152对前列腺癌生化复发早期预测的研究[J].中华男科学杂志,2017,23(7):603-608.
[10] 郭婧澜,叶婷. miRNA在泌尿系统肿瘤发病、诊断及治疗中的作用研究进展[J].山东医药,2016,56(35):108-111.
[11] 葛增乐,许斌,陈明. 长链非编码RNA在前列腺癌的研究进展[J].东南大学学报:医学版,2016,26(3):431-436.
[12] 丁翔,崔凤梅,侯建全,等. 前列腺癌患者血清微小RNA表达谱的初步研究[J].中华泌尿外科杂志,2015,36(3):225-228.